Department of Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Neuro-oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Shields Warren 430 D, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2022 Feb;36(1):113-132. doi: 10.1016/j.hoc.2021.08.007. Epub 2021 Oct 30.
Isocitrate dehydrogenase (IDH) 1 and 2 mutations represent essential components for the diagnosis of diffuse astrocytic tumors and oligodendroglioma. IDH wild-type glial tumors include a wide spectrum of tumors with differences in prognosis and recommended therapeutic approaches. Tumors characterized as molecular glioblastoma in the World Health Organization 2021 classification should be treated according to the glioblastoma therapeutic principles and included in glioblastoma trials. Improving on existing treatments options including targeted and immunotherapy approaches is imperative for most patients with IDH wild-type glial tumors, and enrollment in clinical trials is encouraged.
异柠檬酸脱氢酶（IDH）1 和 2 突变是诊断弥漫性星形细胞瘤和少突胶质细胞瘤的重要组成部分。IDH 野生型神经胶质瘤包括广泛的肿瘤谱，其预后和推荐的治疗方法存在差异。在 2021 年世界卫生组织分类中被定义为分子胶质母细胞瘤的肿瘤应根据胶质母细胞瘤的治疗原则进行治疗，并纳入胶质母细胞瘤临床试验。对于大多数 IDH 野生型神经胶质瘤患者来说，改善现有的治疗方案，包括靶向治疗和免疫治疗方法是至关重要的，鼓励他们参加临床试验。
